These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
316 related articles for article (PubMed ID: 12075699)
1. Update on the management of ovarian cancer. Ozols RF Cancer J; 2002; 8 Suppl 1():S22-30. PubMed ID: 12075699 [TBL] [Abstract][Full Text] [Related]
2. Recent advances in the management of women with ovarian cancer. Eltabbakh GH Minerva Ginecol; 2004 Feb; 56(1):81-9. PubMed ID: 14973412 [TBL] [Abstract][Full Text] [Related]
3. Effect of adjuvant paclitaxel and carboplatin for advanced stage epithelial ovarian cancer: a population-based cohort study of all patients in western Sweden with long-term follow-up. Akeson M; Zetterqvist BM; Dahllöf K; Brännström M; Horvath G Acta Obstet Gynecol Scand; 2008; 87(12):1343-52. PubMed ID: 18951208 [TBL] [Abstract][Full Text] [Related]
13. [Treatment of ovarian cancer]. Cianti C Clin Ter; 2002; 153(2):135-44. PubMed ID: 12078339 [TBL] [Abstract][Full Text] [Related]
14. Advances in the management of epithelial ovarian cancer. Berkenblit A; Cannistra SA J Reprod Med; 2005 Jun; 50(6):426-38. PubMed ID: 16050567 [TBL] [Abstract][Full Text] [Related]
15. Surgical cytoreduction in recurrent ovarian carcinoma in patients with complete response to paclitaxel-platinum. Gronlund B; Lundvall L; Christensen IJ; Knudsen JB; Høgdall C Eur J Surg Oncol; 2005 Feb; 31(1):67-73. PubMed ID: 15642428 [TBL] [Abstract][Full Text] [Related]
16. The results of treatment of epithelial ovarian cancer after centralisation of primary surgery. Results from North Jutland, Denmark. Soegaard Andersen E; Knudsen A; Svarrer T; Lund B; Nielsen K; Grove A; Tetsche M Gynecol Oncol; 2005 Dec; 99(3):552-6. PubMed ID: 16150480 [TBL] [Abstract][Full Text] [Related]
17. Maspin expression in epithelial ovarian cancer and associations with poor prognosis: a Gynecologic Oncology Group study. ; Secord AA; Lee PS; Darcy KM; Havrilesky LJ; Grace LA; Marks JR; Berchuck A Gynecol Oncol; 2006 Jun; 101(3):390-7. PubMed ID: 16551475 [TBL] [Abstract][Full Text] [Related]
18. Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens. du Bois A; Weber B; Rochon J; Meier W; Goupil A; Olbricht S; Barats JC; Kuhn W; Orfeuvre H; Wagner U; Richter B; Lueck HJ; Pfisterer J; Costa S; Schroeder W; Kimmig R; Pujade-Lauraine E; ; ; J Clin Oncol; 2006 Mar; 24(7):1127-35. PubMed ID: 16505432 [TBL] [Abstract][Full Text] [Related]
19. Prognostic factors for high-risk early-stage epithelial ovarian cancer: a Gynecologic Oncology Group study. Chan JK; Tian C; Monk BJ; Herzog T; Kapp DS; Bell J; Young RC; Cancer; 2008 May; 112(10):2202-10. PubMed ID: 18348296 [TBL] [Abstract][Full Text] [Related]
20. [First line chemotherapy of advanced epithelial ovarian cancer]. Lhommé C; Even C; Morice P; Balleyguier C; Petrella M; Gouy S; Uzan C; Duvillard P; Pautier P Bull Cancer; 2009 Dec; 96(12):1207-13. PubMed ID: 19948450 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]